AMENDED AND RESTATED LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT DATED AS OF MARCH 31, 2013 BY AND AMONG ONYX PHARMACEUTICALS, INC. AND ONYX THERAPEUTICS, INC. AND ONO PHARMACEUTICAL CO., LTD.License Agreement • May 8th, 2013 • Onyx Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
This Amended and Restated License, Development and Commercialization Agreement (this “Agreement”) amends and restates the License, Development and Commercialization Agreement dated as of September 7, 2010 (the “2010 Agreement”) by and among Onyx Pharmaceuticals, Inc., a Delaware corporation, and Onyx Therapeutics, Inc., a Delaware corporation (together referred to as, “Onyx”), and Ono Pharmaceutical Co., Ltd., a Japanese stock corporation (“Ono”) and shall be entered into as of the 2013 Effective Date (as defined below). Onyx and Ono are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
March 12, 2013 John Osborn c/o Onyx Pharmaceuticals, Inc. South San Francisco, CA 94080 Re: Separation Agreement Dear John:Separation Agreement • May 8th, 2013 • Onyx Pharmaceuticals Inc • Biological products, (no disgnostic substances) • California
As discussed, this letter sets forth the terms of the separation agreement (the “Agreement”) between you and Onyx Pharmaceuticals, Inc. (“Onyx” or the “Company”).
